

**Note:** This draft is only intended as a copy for comments during the stakeholder consultation period of the proposed guidelines. The content of this draft may change and does not prejudice any policy nor decision of the FDA. Citation of any text in this draft, for purposes other than the submission of comments as indicated in the issued announcement, is not recommended.

1  
2  
3  
4 **FDA CIRCULAR**

5 No. \_\_\_\_\_  
6  
7

8 **SUBJECT :**            **Guidelines on the Filing and Submission of Acceptable Variations**  
9                            **on Protocols and Non-standard Protocols for the Review and Pre-**  
10                           **Approval by the Food and Drug Administration Prior to the**  
11                           **Conduct of Bio-efficacy Test Studies of Household Pesticides for the**  
12                           **Purposes of Securing a Certificate of Product Registration**  
13

---

14  
15 **I.        RATIONALE**

16  
17 Pesticide registration involves an evaluation of comprehensive scientific data  
18 demonstrating that a pesticide is effective for its intended purposes and does not pose  
19 an unacceptable risk to human or animal health or the environment. In particular, the  
20 aspect of pesticide registration which reviews the effectiveness of a pesticide is the  
21 technical evaluation of the submitted bio-efficacy study. Following Department of  
22 Health (DOH) Administrative Order (AO) No. 2019-0008, entitled, "New Rules and  
23 Regulations in the Registration of Household Pesticide Products and their Active  
24 Ingredients", accepted protocols have been identified and that any deviation from  
25 standard protocols require sufficient and compelling justification to ensure soundness  
26 of the method and the reliability to produce data to support product claims.  
27

28 In the course of the implementation of the said AO, updates to the internationally-  
29 accepted standards suggest that changes to the list of accepted protocols must be made.  
30 Additionally, an assessment of the implementation of the AO showed that pesticide  
31 registration applications were found to display deficiencies in the submitted bio-  
32 efficacy test study which resulted in disapproved applications. Such applications  
33 displayed failure to substantiate claims and failure to justify modifications to accepted  
34 standards. In order to assist market authorization applicants, promote regulatory  
35 compliance, and ensure the efficient use of resources, this Circular hereby establishes  
36 the pre-approval process for modified and non-standard bio-efficacy test protocols.  
37

38  
39 **II.       OBJECTIVES**

40  
41 This Circular aims to improve the regulatory compliance of pesticide registration  
42 applications and facilitate the same through the establishment of a pathway for the  
43 review and pre-approval of non-standard and modified bio-efficacy test protocols,  
44 which will be submitted in support of pesticide registration under DOH AO No. 2019-  
45 0008.  
46

47  
48 **III.      SCOPE**

1  
2 This Circular shall cover household pesticide products pursuant to the definition and  
3 scope provided by DOH AO No. 2019-0008 and the establishments that are engaged in  
4 the manufacture, importation, exportation, sale, offer for sale, distribution, donation,  
5 transfer, and where applicable, the use, testing, promotion, advertising, or sponsorship  
6 of such household pesticide products.  
7  
8

9 **IV. GENERAL GUIDELINES**

- 10  
11 A. The applicant for pesticide registration shall be a holder of a valid License to  
12 Operate (LTO) as a Household Pesticide Establishment issued by the FDA.  
13 Consequently, applicants seeking the review and approval of its non-standard  
14 or modified test protocol shall also be a licensed Household Pesticide  
15 Establishment.  
16  
17 B. All household pesticides shall preferably be tested in accordance with existing  
18 accepted protocols as listed in Annex A. Bio-efficacy tests conducted in strict  
19 adherence to existing accepted protocol shall directly proceed to pesticide  
20 registration under DOH AO No. 2019-0008.  
21  
22 C. Where a bio-efficacy test to be conducted for the purposes of applying for a  
23 household pesticide registration utilizes a non-standard protocol or where  
24 justifiable circumstances require deviations from accepted test protocols,  
25 licensed household pesticide establishments shall submit the said modified or  
26 non-standard test protocol to the FDA for review and approval prior the conduct  
27 of the bio-efficacy test study and any subsequent pesticide registration.  
28  
29 D. Applications for the pre-approval of non-standard and modified bio-efficacy test  
30 protocols shall be filed following the procedure outlined in Section V.A. and  
31 the requirements provided in Section V.B.  
32  
33 E. Market authorization holders (MAHs) intending to use and strictly apply a bio-  
34 efficacy protocol previously approved following these Guidelines for a different  
35 pesticide registration application may conduct and present data on bio-efficacy  
36 studies generated using the accepted protocol; Provided, the product type,  
37 intended use and manner of use shall be similar to as the previously approved  
38 bio-efficacy protocol; Provided, further, that that the market authorization  
39 applicant of the pesticide registration application shall be the same as the  
40 applicant of the previously approved bio-efficacy protocol.  
41  
42

43 **V. SPECIFIC GUIDELINES**

44  
45 Applications for pre-approval of bio-efficacy test protocols shall be filed in accordance  
46 with the following procedure and requirements:  
47

48 **A. Filing of an application**  
49

1 Each application shall contain a single protocol which is a modification of an  
2 existing protocol or a non-standard protocol. An application shall be filed  
3 following the procedure outlined in Annex B. An application is considered final  
4 upon submission of complete requirements, following pre-assessment,  
5 including payment of the required fees and charges. Incomplete applications  
6 shall be returned to the applicant.  
7

8 A successful filing following pre-assessment shall not be construed as an  
9 approval of the application, wherein the comprehensive evaluation for  
10 correctness and compliance to administrative and technical standards is  
11 performed in the evaluation step.  
12

13 **B. Documentary Requirements**

- 14
- 15 1. Letter of Intent specifying the reason for utilizing a non-standard or
  - 16 modified bio-efficacy test protocol
  - 17 2. Integrated application form
  - 18 3. Valid LTO
  - 19 4. Copy of official receipt
  - 20 5. Test Protocol
- 21

22

23 The test protocols shall contain the information as listed in Annex C.  
24

25 **C. Evaluation**

26

27 The evaluation of the submitted test protocols shall be based on the  
28 correctness, accuracy, and compliance with administrative and technical  
29 standards of the submitted documents.  
30

31 **D. Processing time**

32

33 The duration of the review and pre-approval of the submitted test protocols shall  
34 be twenty (20) working days. The processing time may be extended for the same  
35 number of days with prior notice to the applicant.  
36

37 **E. Fees and Charges**

38

39 An application fee of Php 500, and the corresponding Legal Research Fee, shall  
40 be charged for applications for the review and pre-approval of test protocols,  
41 following DOH AO No. 50 s. 2001.  
42

43 **F. Result of application**

44

45 The result of the application shall be issued by the FDA to the email address of  
46 the applicant declared in the application form.  
47

48

49 **VI. TRANSITORY PROVISIONS**

50

1 Applications submitted prior the effectivity of this issuance shall be processed in  
2 accordance with DOH AO No. 2019-0008. Upon effectivity of this Circular, new  
3 applications shall adhere to the guidelines set forth in this Circular.  
4

5  
6 **VII. PENALTY CLAUSE**  
7

8 Applicable sanctions or regulatory actions shall be imposed upon those found in  
9 violation of the provisions of this Circular.  
10

11  
12 **VIII. REPEALING CLAUSE**  
13

14 All other administrative issuances, bureau circulars and memoranda and other  
15 regulations inconsistent with this Order are hereby withdrawn, repealed and/or revoked  
16 accordingly.  
17

18  
19 **IX. SEPARABILITY CLAUSE**  
20

21 The provisions of this Memorandum are hereby declared separable and in the event of  
22 any such provision/s is/are declared invalid or unenforceable, the validity of  
23 enforceability of the remaining portions or provisions which are not affected, shall  
24 remain in full force and in effect.  
25

26  
27 **X. EFFECTIVITY**  
28

29 This Circular shall take effect fifteen (15) days after its publication in a newspaper of  
30 general circulation and filing with the University of the Philippines Law Center Office  
31 of the National Administrative Register.  
32

33  
34  
35  
36 **FRANCISCO T. DUQUE III, MD, MSc**  
37 Secretary of Health  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## ANNEX A

### List of Bio-efficacy Test Studies with accepted Test Protocol/s

#### 1. Human Mosquito Repellent

- 1.1 WHO Guidelines for Efficacy Testing of Mosquito Repellents for Human Skin
- 1.2 OPPTS 810.3700: Insect Repellents to be Applied to Human Skin
- 1.3 MS 1497:2007: Household Insecticide Products – Personal Mosquito Repellent – Evaluation Method for Biological Efficacy (First revision)

#### 2. Insecticides

- 2.1 WHO Guidelines for Efficacy Testing of Insecticides for Indoor and Outdoor Ground-Applied Space Spray Applications (May also be used for houseflies)
- 2.2 ECHA Appendix 18 “List of Currently Available Standard Test Methods for Product Type 18 Insecticides/Acaricides and Product Type 19 Repellents/Attractants (As Far as They Concern Insects and Other Arthropods)”
- 2.3 OCSPP 810.3500: Premises Treatments
- 2.4 WHO Guidelines for Testing Mosquito Adulticides for Indoor Residual Spraying and Treatment of Mosquito Nets (May also be used for houseflies)
- 2.5 MS 1911: Part 1: 2006: Household Insecticide Products – Evaluation Method for Biological Efficacy – Part 1: Glass Chamber Method
- 2.6 MS 1911: Part 2: 2006: Household Insecticide Products – Evaluation Method Biological Efficacy – Part 2: Peet Grady Method
- 2.7 MS 1911: Part 3: 2006: Household Insecticide Products – Evaluation Method for Biological Efficacy – Part 3: Cylinder Method
- 2.8 MS 1911: Part 4: 2006: Household Insecticide Products – Evaluation Method for Biological Efficacy – Part 4: Plaque Method
- 2.9 MS 1984: 2007: Laboratory Colonisation of Insects of Public Health Importance – Guidelines
- 2.10 MS 1985: 2007: Household Insecticide Products – Ant Bait – Evaluation Method for Biological Efficacy
- 2.11 MS 1986: 2007: Household Insecticide Products – Containerised Ant Bait – Specification
- 2.12 MS 1326: Part 3:2007: Household Insecticide Products – Cockroach Bait – Evaluation Method for Biological Efficacy (Second revision)
- 2.13 MS 1326-2:2010: Household Insecticide Products – Containerised Cockroach Bait – Specification (First revision)

#### 3. Insecticidal Net

- 3.1 WHO Guidelines for Laboratory and Field Testing of Long-Lasting Insecticide Nets

#### 4. Mosquito Coils, Vaporizer Mats, Liquid Vaporizers Ambient Emanators and Aerosols

- 4.1 WHO Guidelines for Efficacy Testing of Household Insecticide Products
- 4.2 MS 23 PART 1 2006: Household Insecticide Product – Physical, Chemical and Biological Efficacy Requirements – Mosquito Coil (Fourth revision)
- 4.3 MS1044:2012: Household insecticide products – Mosquito vapourising mat – Specification (Second revision)

- 1           4.4    MS 1255:2006: Household Insecticide Products – Physical, Chemical and
- 2                    Biological Efficacy Requirements – Surface and Direct Spray Aerosol (First
- 3                    revision)
- 4           4.5    MS 1257:2010 Household Insecticide Products – Aerosol Against Flying
- 5                    Insects – Specification (First revision)

6  
7   5. Mosquito Larvicide

- 8           5.1    WHO Guidelines for Laboratory and Field Testing of Mosquito Larvicides

9  
10  
11   6. Termiticide, Wood preservative and Termite baits

- 12           6.1    ASTM D3345: Standard Test Method for Laboratory Evaluation of Solid
- 13                    Wood for Resistance to Termites, ASTM D3345-17 (West Conshohocken,
- 14                    PA: ASTM International, approved January 1, 2017),
- 15                    <https://doi.org/10.1520/D3345-17>
- 16           6.2    OPPTS 810.3800: Method for Efficacy Testing of Termite Baits
- 17           6.3    OPPTS 810.3600: Structural Treatment


18  
19  
20   The afore-mentioned list of bio-efficacy test studies with accepted test protocols may be

21   amended or updated as determined by FDA.

22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

ANNEX B  
Step-by-step Application Procedure

1. Pathways for pre-approval of Bio-efficacy test protocols



1 2. Application procedure for the review and pre-approval of test protocols:  
2

- 3 2.1 Applicant sends a request for schedule of submission of application  
4 requirements to FDAC (fdac.pacd@fda.gov.ph). Requests for schedule may be  
5 submitted from Monday to Friday. The schedule of the applications for pre-  
6 assessment is on Thursdays, except for Holidays, from 8AM to 12NN.  
7 2.2 Applicant submits the application requirements for pre-assessment to FDAC  
8 (fdac.pacd@fda.gov.ph) on the day of the schedule, from 8AM to 12NN. Only  
9 applications with complete requirements pre-assessed by the Center shall  
10 proceed to payment.  
11 2.3 Applicant pays for the corresponding fee.  
12 2.4 Applicant submits the paid application (electronic copies of the complete  
13 requirements) to FDAC ([fdac.pacd@fda.gov.ph](mailto:fdac.pacd@fda.gov.ph)).  
14 2.5 The FDA forwards the application to the Center.  
15 2.5 The Center receives and forwards the application to Center's HUP Consultant.  
16 2.6 The Center's HUP Consultant evaluates the correctness of the documents and  
17 renders the final decision.  
18 2.8 Releasing of the final issued document.  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50



1  
2  
3  
4  
5  
6

**ANNEX C**  
**Test Protocol Content**

The test protocol/s shall contain the following information:

<p><b>Background</b> (combining the introduction, objective and literature review)</p>	<p>Information on the Product</p> <ul style="list-style-type: none"><li>• product owner</li><li>• product classification</li><li>• formulation type</li><li>• identity and concentration of the active ingredient/s</li><li>• available information on the efficacy of the active ingredient/s against the intended target pest</li><li>• available information on the toxicity of the active ingredients, both acute and chronic toxicity</li><li>• available information on resistance and cross-resistance of target pests against the active ingredient/s</li><li>• information whether the test/s have been previously accepted by other regulatory agency</li></ul> <p>Purpose of the proposed test</p> <ul style="list-style-type: none"><li>• specific claim of the household pesticide (includes field of use, mode of application, target pest/s, dilution rate, application rate, frequency of re-application)</li></ul> <p>Justification/Reason for the modified or non-standard protocol</p> <ul style="list-style-type: none"><li>• Existing accepted protocol, if available</li><li>• compelling reason for the modification or use of non-standard test protocol</li></ul>
<p><b>Methodology</b></p>	<p>Test Duration</p> <p>Test insect/s</p> <ul style="list-style-type: none"><li>• species (in binomial nomenclature)</li><li>• source (i.e. laboratory-reared, wild-collected)<ul style="list-style-type: none"><li>• rearing technique for laboratory-reared target insect/s including environmental conditions and food</li></ul></li><li>• age and sex</li></ul> <p>Positive Control</p> <ul style="list-style-type: none"><li>• registered HUP product with the same active ingredient/s or active ingredient belonging from the same chemical family</li><li>• include the HSR number</li></ul> <p>Negative Control</p> <p>Test Procedure including but not limited to:</p> <ul style="list-style-type: none"><li>• environmental conditions</li><li>• acclimatization of test insect/s</li><li>• mode of application</li><li>• dilution rate,</li><li>• application rate</li><li>• size of the test<ul style="list-style-type: none"><li>• number of test insect/s per replicate</li><li>• number of replicates (min. of 3)</li></ul></li><li>• test area / facility / equipment</li></ul>

	<ul style="list-style-type: none"> <li>• laboratory trial: design of chamber including material and dimension, cleaning/washing protocol, etc</li> <li>• field trial: plot size, selection criteria for the test location, equipment design, cleaning/washing protocol, etc</li> <li>• schedule of observation</li> <li>• efficacy Parameter</li> <li>• in case of modified protocol, include a description of the modifications made in their respective sections</li> </ul> <p>Statistical Analysis</p> <p>In case human subjects are part of the proposed test protocol, include the selection criteria, copy of informed consent form, certification/approval from a Research Ethics Committee</p>
References	Include in-text citation, reference list at the end of the document and pdf copies of the references

1  
2  
3  
4  
5  
6  
7  
8

DRAFT